Literature DB >> 21715722

Does use of the adjuvant! model influence use of adjuvant therapy through better risk communication?

Jeffrey K Belkora1, David W Hutton, Dan H Moore, Laura A Siminoff.   

Abstract

Adjuvant! is a model that provides recurrence and mortality risk predictions for patients with breast cancer considering adjuvant therapies. Although low-risk patients who saw Adjuvant! chose adjuvant therapy less frequently, whether this was because of educational or other aspects of the decision aid is unknown. The authors explored whether Adjuvant! affects choice of therapy through increased patient knowledge. A subset of data were analyzed from a cluster randomized trial in which oncology practices in 2 major United States cities were randomly assigned to use either Adjuvant! or an informational pamphlet to educate patients. Of 405 patients, 48 were low-risk, with 28 assigned to the decision aid and 20 to the pamphlet. Among the low-risk patients, using frequency tables and Fisher exact tests, the authors explored whether Adjuvant! was associated with more accurate patient estimates of survival; whether accuracy was associated with treatment choice; and whether, after controlling for accuracy, any remaining association was seen between Adjuvant! and treatment choice. Adjuvant! was associated with more accurate estimates of baseline prognosis compared with the pamphlet (57% vs. 25%; P = .04). Patients who had more accurate estimates of baseline prognosis were less likely to choose adjuvant therapy (62% vs. 89%; P = .04). After controlling for accuracy, no statistically significant association was found between the use of Adjuvant! and adjuvant therapy (P = .59 and P = .11 for inaccurate and accurate patients, respectively). Adjuvant! seems to influence patient choice through educational rather than other means of persuasion. However, many patients held inaccurate risk perceptions after viewing Adjuvant!.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715722      PMCID: PMC3528013          DOI: 10.6004/jnccn.2011.0061

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  16 in total

1.  What does it mean to understand a risk? Evaluating risk comprehension.

Authors:  N D Weinstein
Journal:  J Natl Cancer Inst Monogr       Date:  1999

Review 2.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; H J Senn
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

3.  The 1998 St. Gallen's Consensus Conference: an assessment.

Authors:  J Zujewski; E T Liu
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

4.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Authors:  Ivo A Olivotto; Chris D Bajdik; Peter M Ravdin; Caroline H Speers; Andrew J Coldman; Brian D Norris; Greg J Davis; Stephen K Chia; Karen A Gelmon
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

5.  Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.

Authors:  Pamela B Peele; Laura A Siminoff; Ying Xu; Peter M Ravdin
Journal:  Med Decis Making       Date:  2005 May-Jun       Impact factor: 2.583

6.  Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.

Authors:  Isaac M Lipkus; Ellen Peters; Gretchen Kimmick; Vlayka Liotcheva; Paul Marcom
Journal:  Med Decis Making       Date:  2010-02-16       Impact factor: 2.583

7.  Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.

Authors:  Timothy Whelan; Carol Sawka; Mark Levine; Amiram Gafni; Leonard Reyno; Andrew Willan; Jim Julian; Susan Dent; Hakam Abu-Zahra; Edmond Chouinard; Richard Tozer; Kathleen Pritchard; Ilona Bodendorfer
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

8.  A computer based program to assist in adjuvant therapy decisions for individual breast cancer patients.

Authors:  P M Ravdin
Journal:  Bull Cancer       Date:  1995-12       Impact factor: 1.276

9.  A computer program to assist in making breast cancer adjuvant therapy decisions.

Authors:  P M Ravdin
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

Review 10.  Decision aids for people facing health treatment or screening decisions.

Authors:  A M O'Connor; D Stacey; V Entwistle; H Llewellyn-Thomas; D Rovner; M Holmes-Rovner; V Tait; J Tetroe; V Fiset; M Barry; J Jones
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  4 in total

1.  Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Authors:  Clara N Lee; Matthew H Wetschler; Yuchiao Chang; Jeffrey K Belkora; Beverly Moy; Ann Partridge; Karen R Sepucha
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-20       Impact factor: 2.796

2.  Use of a computerised decision aid (DA) to inform the decision process on adjuvant chemotherapy in patients with stage II colorectal cancer: development and preliminary evaluation.

Authors:  A Miles; I Chronakis; J Fox; A Mayer
Journal:  BMJ Open       Date:  2017-03-24       Impact factor: 2.692

3.  Identification of Requirements for a Postoperative Pediatric Pain Risk Communication Tool: Focus Group Study With Clinicians and Family Members.

Authors:  Michael D Wood; Kim Correa; Peijia Ding; Rama Sreepada; Kent C Loftsgard; Isabel Jordan; Nicholas C West; Simon D Whyte; Elodie Portales-Casamar; Matthias Görges
Journal:  JMIR Pediatr Parent       Date:  2022-07-15

4.  Breast cancer specialists' views on and use of risk prediction models in clinical practice: a mixed methods approach.

Authors:  Ellen G Engelhardt; Arwen H Pieterse; Nanny van Duijn-Bakker; Judith R Kroep; Hanneke C J M de Haes; Ellen M A Smets; Anne M Stiggelbout
Journal:  Acta Oncol       Date:  2014-10-13       Impact factor: 4.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.